Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="1" name="CC Event Nav"]

Comparison of Costs and Healthcare Resource Utilization in Patients with CLL Treated with Frontline Ibrutinib or Chemoimmunotherapy

Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL

Single-Agent Ibrutinib versus Chemoimmunotherapy Regimens for Treatment-Naïve Patients with CLL: A Cross-Trial Comparison

Prolonged Improvement in PROs and Well-Being in Older Patients with Treatment-Naïve CLL Treated with Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study

Improvements in Remission and Low Disease Activity Achieved with Ongoing Sarilumab Treatment in Patients with RA

Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA

Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA

Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA

Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA

Page 12 of 25
Results 111 - 120 of 242